Pancragen (KEDW): The Pancreatic Bioregulator Peptide, Evidence Reviewed
Pancragen is a Khavinson tetrapeptide (Lys-Glu-Asp-Trp) studied for restoring age-related pancreatic islet function. This review covers its rat, primate, and small human diabetes studies, and is honest about where the evidence stops.
This article is for educational purposes and is intended for healthcare practitioners and informed readers. It does not constitute medical advice or therapeutic guidance. Pancragen is a research compound, not approved as a medicine in Australia or most Western jurisdictions.
1. Where Pancragen Sits in the Khavinson Programme
Pancragen is the tetrapeptide Lys-Glu-Asp-Trp, developed within the same St. Petersburg Institute of Bioregulation and Gerontology research programme that produced Epitalon, Vilon, Livagen, Thymalin, and the other short-peptide bioregulators. The proposed mechanism is the same tissue-specific chromatin framework described across that research line: a peptide derived from a given tissue extract is hypothesised to selectively restore access to genes that are active in young tissue of that type but progressively silenced by heterochromatin expansion with age. Pancragen's proposed target is the pancreas, specifically the acinar (digestive enzyme-producing) and islet (hormone-producing) cell populations.
For the broader mechanistic framework, the chromatin hypothesis, and an honest accounting of where this research programme's evidence is strong and where it is thin, see the overview of peptide bioregulators. This article focuses narrowly on what has actually been published about Pancragen itself.
What sets Pancragen apart from most of the bioregulator catalogue reviewed on this site is that its published evidence base includes rodent and non-human primate metabolic studies, and one small human study in elderly patients with type 2 diabetes, rather than being confined to lymphocyte chromatin cytology. That is a meaningfully different evidence profile, and it is worth examining on its own terms rather than folding it into the general bioregulator narrative.
2. Cell Differentiation Evidence: Pdx1, Ptf1a, and the Islet Transcription Factors
The most mechanistically detailed Pancragen paper is a 2013 study by Khavinson, Durnova, and colleagues published in the Bulletin of Experimental Biology and Medicine, examining pancreatic cell cultures from young and aged tissue (PMID 23486591). The authors reported that expression of differentiation markers declines in ageing pancreatic cells, and that Pancragen exposure increased expression of acinar differentiation factors (Pdx1, Ptf1a) and islet differentiation factors (Pdx1, Pax6, Pax4, Foxa2, Nkx2.2) in aged cultures toward levels seen in young cultures.
Pdx1, Pax4, Pax6, Foxa2, and Nkx2.2 are not arbitrary markers. They are core transcription factors in the developmental programme that specifies pancreatic islet cell identity and maintains beta-cell function in adult tissue; their decline is a recognised feature of pancreatic ageing in the broader endocrinology literature, independent of anything to do with bioregulators. What the Khavinson group is claiming is narrower and more falsifiable than a generic "anti-ageing" effect: that a four-amino-acid peptide added to a cell culture dish shifts expression of this specific, well-characterised transcription factor set back toward a younger profile. That is a testable, cell-culture-level claim, and it has not, to this author's knowledge, been independently replicated by a laboratory outside the Khavinson group's own network.
3. Rodent Diabetes Model
An earlier study by Khavinson and colleagues, published in 2007 in the same journal, tested Pancragen in Wistar rats with streptozotocin-induced diabetes, a standard rodent model of pancreatic beta-cell destruction (PMID 18642713). Oral Pancragen produced a measurable reduction in blood glucose during the treatment period. Intramuscular Pancragen separately normalised an abnormality in mesenteric capillary endothelial cell adhesion seen in the diabetic rats, though it did not change capillary permeability. The authors interpreted this as evidence of both a glucose-lowering effect and a separate, non-overlapping vascular endothelial effect in early experimental diabetes.
Streptozotocin ablates existing beta cells rather than modelling the chronic insulin-resistance pathway that dominates human type 2 diabetes, so this model speaks more to a peptide's effect in a beta-cell-deficient state than to insulin resistance specifically. It is a legitimate and commonly used diabetes model, but readers should not read the oral hypoglycaemic finding here as equivalent to a type 2 diabetes result; the later primate and human studies are more directly relevant to that question.
4. Non-Human Primate Study: Aged Rhesus Monkeys
A 2014 study by Goncharova, Khavinson, and colleagues, published in Advances in Gerontology, is the strongest preclinical data point for Pancragen (PMID 25946840). The study compared glucose tolerance testing in old versus young female rhesus monkeys, then treated the old animals with Pancragen (50 micrograms per animal per day, intramuscularly, for 10 days) and re-tested them.
Before treatment, the old monkeys showed the expected age-related pattern: a slower glucose "disappearance" rate after a standard glucose load, and higher, more dysregulated insulin and C-peptide peaks at 5 and 15 minutes post-injection, consistent with early insulin resistance and compensatory hyperinsulinaemia. After the 10-day Pancragen course, glucose disappearance markedly improved and the insulin and C-peptide response patterns normalised toward the young-animal profile. Notably, the authors reported that this recovery was partially sustained three weeks after Pancragen was discontinued, suggesting an effect on underlying islet function rather than a purely acute pharmacological action.
Rhesus monkeys are a closer physiological model to humans than rodents for pancreatic endocrine function, and a 10-day intervention producing a multi-week sustained effect is a more interesting signal than a transient glucose-lowering effect would be. It remains, however, a small, uncontrolled-for-blinding animal study from a single research group, and primate data of this kind has not been independently replicated elsewhere in the indexed literature.
5. The Human Study: Elderly Patients With Type 2 Diabetes
The only human data on Pancragen comes from a 2011 study by Korkushko, Khavinson, and colleagues at the Institute of Gerontology of the National Academy of Medical Sciences of Ukraine, published in the Bulletin of Experimental Biology and Medicine (PMID 22448364). The study examined 30 healthy older adults and 33 older adults with type 2 diabetes. Nocturnal melatonin production was 70% lower in the diabetic group than in the healthy comparison group, consistent with a broader literature linking pineal melatonin decline to insulin resistance in ageing. Patients with type 2 diabetes who received Pancragen showed significant reductions in fasting glucose, glucose tolerance test values, plasma insulin, and an insulin resistance index, while patients who did not receive it showed no change in these measures over the same period.
A few things should be stated plainly about this study rather than left implied. The published abstract does not describe a randomised design, blinding, or a placebo arm, and it is not large: 33 diabetic participants split into treated and comparison groups is a small sample for a metabolic outcomes study. This is a preliminary human signal, not a result that would clear the bar for a treatment claim in an Australian or other Western regulatory context, and it should not be presented to patients as established clinical evidence. It is, however, a real step beyond cell culture and animal data, and it is more than most compounds in the bioregulator catalogue can currently claim.
The melatonin-insulin resistance link the authors invoke is itself a legitimate area of endocrinology independent of Pancragen; circadian and pineal function genuinely interact with glucose metabolism in ageing. That is worth separating from the Pancragen-specific claim: the melatonin finding is better-established background, while the Pancragen treatment effect in this small, non-randomised-as-reported sample is the part that still needs confirmation.
6. Regulatory Status and Research Context
Pancragen holds no regulatory approval as a therapeutic agent in Australia or any other Western jurisdiction. It is not evaluated or scheduled by the Therapeutic Goods Administration for any specific indication, and it is not registered for prescription use. It is available internationally through research-compound suppliers and is not approved for human therapeutic use outside investigational settings. As with other bioregulators discussed on this site, the publication record is concentrated almost entirely within the Khavinson research network and its direct collaborators (the St. Petersburg Institute of Bioregulation and Gerontology, the Pavlov Institute of Physiology, and the Kiev Institute of Gerontology), rather than spread across independent laboratories internationally. That concentration is a genuine limitation when assessing how much weight the findings should carry, regardless of how internally consistent the results appear across the rat, primate, and human studies.
7. Considerations for Integrative Practitioners
For practitioners fielding patient questions about Pancragen, several points are worth holding onto. The mechanistic story, that islet transcription factor expression declines with age and that restoring chromatin accessibility at those loci could improve beta-cell function, is coherent and engages real, independently documented biology (Pdx1 and the islet transcription factor network are well established outside the bioregulator literature). The rat and primate data show a consistent direction of effect across models. The human data, while real and from a peer-reviewed publication, is small, comes from a single research group, and does not include the methodological detail (randomisation, blinding) that would be needed to treat it as confirmatory.
This evidence profile sits meaningfully above the chromatin-cytology-only data available for compounds like Vilon and Livagen, reviewed in our piece on those two bioregulators, but well below what would be required to recommend Pancragen as an established intervention for insulin resistance or type 2 diabetes. For the broader, better-established naturopathic and functional-medicine toolkit for insulin resistance, including nutrient, lifestyle, and evidence-graded supplement approaches that do not carry the same regulatory and replication caveats, see our review of insulin resistance mechanisms.
Patients researching Pancragen online are likely to encounter vendor pages presenting this evidence as more settled than it is. The most useful thing a practitioner can do is draw the line accurately: real peer-reviewed preclinical and small human signal, not yet independently replicated, not a substitute for established diabetes management.
8. Summary
Pancragen (Lys-Glu-Asp-Trp) is a Khavinson-programme tetrapeptide studied for pancreatic islet and acinar cell function. Published data spans a rat streptozotocin-diabetes model, a pancreatic cell culture differentiation study, an aged rhesus monkey glucose tolerance study, and one small human study in elderly patients with type 2 diabetes. The direction of effect is consistent across all four: improved glucose handling and normalised islet-associated markers. The evidence is real and peer-reviewed, but it comes from a small, closely affiliated group of researchers, the human data is preliminary and lacks confirmed randomisation, and independent replication outside this research network has not appeared in the indexed literature. That combination places Pancragen in a genuinely promising but clearly unconfirmed category, not a established therapeutic one.
References: Khavinson VKh et al. Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus. Bull Exp Biol Med. 2007;144(4):559-562; PMID 18642713. Khavinson VKh, Durnova AO, et al. Effects of pancragen on the differentiation of pancreatic cells during their ageing. Bull Exp Biol Med. 2013;154(4):501-504; PMID 23486591. Goncharova ND, Khavinson VKh, et al. Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys. Adv Gerontol. 2014;27(4):662-667; PMID 25946840. Korkushko OV, Khavinson VKh, et al. Prospects of using pancragen for correction of metabolic disorders in elderly people. Bull Exp Biol Med. 2011;151(4):454-456; PMID 22448364.